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The federal regulation of biotechnology is governed by a
comprehensive policy recently promulgated by the Office
of Science and Technology Policy. This article examines
and evaluates the developmental history and structure
of this policy for biotechnology. It is the author's opinion
that the present policy contains a series of suppositions
which work to reduce the degree of information known
about engineered organisms and the dangers they may
pose. These suppositions are traced to two sources. First,
to an excessive concern with the costs of regulation; and
second, to an approach which seeks to solve problems of
policy judgement through appeals to science. The author
argues that this approach misdirects the regulation of
engineered organisms, exempting too many of them from
regulatory scrutiny. In conclusion, the author proposes
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means of reforming the policy so that the risk assess-
ment process takes account of factors unique to geneti-
cally modified organisms and so that the risk manage-
ment process is capable of tracking the global
environmental effects of biotechnology without unduly
hampering industry.
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I. Introduction
Recent advances in precise techniques for genetic manip-
ulation have revolutionized the field of biotechnology in a
manner akin to the introduction of steam power to the manu-
facturing process. New techniques have created living bacte-
rial factories that produce medicines such as insulin,' plants
more resistant to pesticides or pests,2 bacteria that protect
crops from frost damage, s and tomatoes with shelf-lives of
three weeks.4 These advances, however, overlay a millennia-
old history. In its cruder forms, biotechnology has been used
to produce beer, wine, and cheeses, as well as to selectively
breed plants and livestock. Genetic engineering can thus be
viewed either as a step in the long evolution of biotechnology
or as a radical break, or revolution, in that process. The ten-
sion between these two perspectives accounts for much of the
controversy surrounding the regulation of biotechnology.
This article focuses on an area of biotechnology com-
monly known as the "environmental release" of genetically
modified organisms. Such organisms may be plants, as is the
case with the pesticide resistant plants mentioned above, or
they may be microorganisms such as the "ice-minus" strain of
bacteria. Unlike insulin-producing bacteria, which carry out
production in safely sealed laboratory environments, this class
of biotechnology products is useful only in relatively large, un-
enclosed spaces such as a tobacco field, or oil spill, on the
open ocean.'
Genetically modified organisms designed for environmen-
tal release appear harder to control - and thus potentially
1. THE PRESIDENT'S COUNCIL ON COMPETITIVENESS, REPORT ON NATIONAL Bio-
TECHNOLOGY POLICY 2-3 (1991) [hereinafter COMPETITIVENESS COUNCIL].
2. U.S. CONGRESS, OFFICE OF TECHNOLOGY ASSESSMENT, NEW DEVELOPMENTS IN
BIOTECHNOLOGY - FIELD TESTING ENGINEERED ORGANISMS: GENETIC AND ECOLOGICAL
ISSUES, OTA-BA-350, 5 (1988) [hereinafter NEW DEVELOPMENTS IN BIOTECHNOLOGY].
3. Id. at 7.
4. U.S. Proposes Deregulating Calgene's Biotech Tomato, N.Y. TIMES, July 14,
1992, at D4.
5. For a more comprehensive overview of environmental applications of geneti-
cally modified organisms, see NEw DEVELOPMENTS IN BIOTECHNOLOGY, supra note 2, at
125-33.
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more dangerous - than organisms safely contained within a
test tube. Ecologists and others point to the possibility that
these new organisms might disrupt native ecosystems in irre-
versible ways.' These organisms have, therefore, received a
large share of the regulatory attention directed toward bio-
technology.7 Indeed, even today, only a very few such orga-
nisms have been allowed to progress to the small-scale field
testing stage.8
Supporters of industry, as well as scientists, have ques-
tioned the stringency of the regulation of environmental re-
leases. They make two principal arguments. First, it is as-
serted that the risks of such organisms are essentially no
greater than the risks of non-modified organisms.' Second, it
is believed that overregulation is stalling an industry that
needs to grow quickly- if it is to win the United States a com-
petitive spot in the global biotechnology market. 10 Biotechnol-
6. See, e.g., James M. Tiedje, et al., The Planned Introduction of Genetically
Engineered Organisms: Ecological Considerations and Recommendations, 70 ECOL-
OGY 298, 301, 304-05 (1989).
7. See generally NEw DEVELOPMENTS IN BIOTECHNOLOGY, supra note 2, at 10, ta-
ble 1.3 (outlining regulatory agency jurisdiction over releases of genetically modified
organisms). Although the initial regulatory concern was with genetic engineering per
se, the confinement levels attainable in the laboratory quickly assuaged fears. Id. at 9.
The focus of the debate has therefore shifted to environmental releases (along with
topics not touched upon in this article, such as gene therapy - the use of genetic
engineering techniques on humans - and the marketing of genetically engineered
foodstuffs, such as the tomato mentioned supra at note 4).
8. For at least a decade prior to the 1986 Coordinated Framework for the Regu-
lation of Biotechnology, 51 Fed. Reg. 23,302 (1986) [hereinafter Coordinated Frame-
work], deliberate release was essentially prohibited. The initial National Institutes of
Health (NIH) Guidelines for Research on Recombinant DNA Molecules strictly pro-
hibited release. 41 Fed. Reg. 27,902, 27,915 (1976). The Guidelines were subsequently
amended to give the NIH Director the power to approve releases on a case by case
basis. 43 Fed. Reg. 60,108 (1978). The Director began approving releases in 1981, 46
Fed. Reg. 40,331 (1981), but the first two approved experiments were postponed due
to technical problems. The third experiment to be approved, a test of an ice-minus
strain of bacteria, 48 Fed. Reg. 24,548, 24,549 (1983), was blocked by a lawsuit
brought by environmentalists under the National Environmental Policy Act (NEPA),
42 U.S.C. §§ 4321-4347 (1988). Foundation on Economic Trends v. Heckler, 756 F.2d
143 (D.C. Cir. 1985).
9. E.g., NATIONAL RESEARCH COUNCIL, FIELD TESTING GENETICALLY MODIFIED OR-
GANISMS: A FRAMEWORK FOR DECISIONS 2, 14-15 (1989) [hereinafter NATIONAL RE-
SEARCH COUNCIL, FRAMEWORK FOR DECISIONS].
10. E.g., COMPETITIVENESS COUNCIL, supra note 1, at 4-5. See also Isaac Rabino,
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ogy regulation, in this view, should involve not only risk anal-
ysis, but also cost-benefit analysis."
The most recent locus of conflict between proponents of
strict regulation and proponents of deregulation is the proper
scope of federal oversight of deliberate releases. At question is
which subset of all genetically modified organisms destined
for environmental release should be subject to federal regula-
tion. For example, industry and some scientists have asserted
that many genetic modifications make organisms no more
dangerous than the parent strain. They argue that certain
classes of genetically modified organisms should be exempted
from federal oversight altogether.' On the other hand, many
ecologists and environmentalists criticize the exemption-based
approach on the grounds that possible health and environ-
mental effects of genetically modified organisms are poten-
tially catastrophic. They argue that when conditions are un-
certain it is unwise to give up all federal oversight through a
program of exemptions."
In a document titled Exercise of Federal Oversight within
Scope of Statutory Authority (the "Federal Oversight" docu-
ment), the Office of Science and Technology Policy (OSTP)
announced a comprehensive policy for the scope of biotech-
nology oversight." This new policy states that the risk of ge-
netically modified organisms should be determined by com-
paring them with past, safe releases of similar, unmodified
The Impact of Activist Pressures on Recombinant DNA Research, 16 Sci., TECH. &
HUMAN VALUES 70, 79 (1991) (82% of U.S. scientists surveyed feared U.S. may lose
biotechnology competitiveness due to "controversy and litigation").
11. Id.
12. Id. at 13-14; NATIONAL RESEARCH COUNCIL, FRAMEWORK FOR DECISIONS, supra
note 9, at 5.
13. Tiedje, et al., supra note 6, at 307-11 (suggesting case by case, rather than
category by category, review, and advocating scaled down oversight rather than ex-
emptions for less risky organisms). The Office of Technology Assessment (OTA) doc-
ument falls somewhere between the Ecological Society of America's position and that
of the NRC and the Competitiveness Council. In its recommendations, the OTA in-
cludes both the exemption and the scaling-down options. NEW DEVELOPMENTS IN BIO-
TECHNOLOGY, supra note 2, at 26-27.
14. Exercise of Federal Oversight within Scope of Statutory Authority: Planned
Introductions of Biotechnology Products into the Environment, 57 Fed. Reg. 6753
(1992) (hereinafter "Federal Oversight").
1992]
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organisms.15 Once risks have been determined, the level of
agency oversight should be such that the social costs of regu-
lating the risk do not exceed the regulation's social benefits.16
Using this cost-benefit method, the Federal Oversight docu-
ment asserts that many types of genetically modified orga-
nisms pose minimal risks in relation to the costs of regulating
them.17 This suggests that agencies might profitably proceed
by exempting broad categories of organisms from federal over-
sight. Marking something of a watershed, both in recent theo-
retical trends in biotechnology regulation and in risk assess-
ment generally, the policy contained in the Federal Oversight
document has become the focal point of the current debate on
the proper regulatory stance toward biotechnology.
This article analyzes the Federal Oversight document.
Part II reviews the administrative history of the document.
Part III identifies the four propositions on which the Federal
Oversight document is based 8 and individually evaluates the
theoretical support for each. Part III.A. examines the idea
that regulation should focus on the risks of the product organ-
ism rather than on the supposed dangers of the process of ge-
netic engineering per se. Part III.B. introduces the concept of
"risk-based" regulation on which the Federal Oversight docu-
ment relies and the cost-benefit approach that the document
brings to risk management. Part III.C. questions the Federal
Oversight document's method of determining an organism's
"familiarity" in order to calculate its risk. Part III.D. analyzes
the use of these risk assessment principles in assigning types
of organisms to regulatory categories, a strategy likely to be
used largely in exempting these organisms from federal
oversight.
Drawing on the criticism developed in Part III, Part IV
presents a proposal for reforming the approach announced in
the Federal Oversight document. First, several aspects of the
system of risk assessment could be made more appropriate to
15. Id. at 6757.
16. Id.
17. Id. at 6755.
18. See infra text accompanying note 48.
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the risks presented by releases of genetically engineered orga-
nisms. Generally, this will correct biases toward underesti-
mating the risks of such organisms and will make the political
content of any system of risk assessment more transparent.
Second, the category approach to risk management should be
replaced by a system of general permitting providing both a
minimal burden to industry and a continuing federal ability to
monitor the long-term and cumulative effects of environmen-
tal release biotechnology.
II. Background of the Scope Debate
The lack of a uniform federal policy concerning the scope
of biotechnology oversight traces back to 1986 when the Rea-
gan Administration established inter-agency biotechnology
regulation under the Coordinated Framework for Regulation
of Biotechnology (Coordinated Framework).19 The Coordi-
nated Framework apportioned responsibility for the regula-
tion of biotechnology among the Environmental Protection
Agency (EPA), the Food and Drug Administration (FDA), the
Occupational Safety and Health Administration (OSHA), and
the Department of Agriculture (USDA). 20 It specified. struc-
tural systems for the coordination of their respective regula-
tory activities, and created an inter-agency committee, the
Biotechnology Science Coordinating Committee (BSCC), to
oversee the process.2 1
In the Coordinated Framework, the OSTP noted that
''any proposal to regulate the research and products of genetic
manipulation techniques will quickly confront the issue of
what organisms should be considered appropriate for certain
types of review. ' ' 22 Individually, each agency published policy
statements containing a scope proposal in which the agency
detailed its plans for extending its existing regulatory author-
19. Coordinated Framework, 51 Fed. Reg. 23,302, 23,334. For an excellent discus-
sion of the administrative politics of the scope issue since 1986, see Sidney A. Sha-
piro, Biotechnology and the Design of Regulation, 17 ECOLOGY L.Q. 1, 27-31 (1990).
20. Hereinafter referred to collectively as "the Agencies."
21. Coordinated Framework, 51 Fed. Reg. 23,302, 23,303-06.
22. Id. at 23,306.
1992]
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ity to include the new technology.2 3 Further, the Coordinated
Framework document contained a tentative scope proposal for
the BSCC, the overseeing agency. This scope proposal sug-
gested federal oversight of two classes of genetically modified
organisms: "inter-generic"24 combinations, and "pathogens."
In establishing these criteria, the BSCC sought public com-
ment to help assess the validity of their decisions.2 5 In addi-
tion to the public criticisms of the BSCC's scope proposal, the
individual agencies themselves also "experienced unantici-
pated difficulty developing operational definitions for regula-
tory purposes."2 6 For example, the scope definition in the
EPA's policy statement in the 1984 proposed Coordinated
Framework received numerous comments.2 " Then, in its 1986
policy statement, the EPA modified its scope definition in a
manner not entirely consistent with the BSCC definition dis-
cussed above. This definition, applicable to the Federal Insec-
ticide, Fungicide and Rodenticide Act (FIFRA)" and the
Toxic Substances Control Act (TSCA)," covered microorga-
nisms used in the environment that "are pathogenic or con-
tain genetic material from pathogens, [or] contain new combi-
nations of traits." 80 This scope definition also was the subject
of much public criticism.
23. See id. at 23,309 (Statement of FDA policy); id. at 23,313 (Statement of EPA
policy); id. at 23,336 (Statement of USDA policy).
24. The term "inter-generic combination" means an organism whose DNA has
elements taken from parent organisms in two or more genera. Id. This type of deriva-
tive organism was thought to be particularly noteworthy because, for the most part,
such combinations do not occur in nature.
25. See id. at 23,306-07. One of the major controversies which ensued was over
the BSCC's decision that an organism modified only through "non-coding regulatory
regions" should not be considered "inter-generic" or a "pathogen." Id. at 23,307; see
generally Shapiro, supra note 19, at 27 and n.163 (discussing controversy over BSCC
determination). The Proposed Oversight document contains a similar exemption. See
infra text accompanying notes 38-39.
26. Principles for Federal Oversight of Biotechnology: Planned Introduction into
the Environment of Organisms with Modified Hereditary Traits, 55 Fed. Reg. 31,118,
31,119 (1990) [hereinafter Proposed Oversight].
27. See Proposed Policy Regarding Certain Microbial Products, 49 Fed. Reg.
50,880 (1984); Coordinated Framework, 51 Fed. Reg. 23,302, 23,315.
28. FIFRA §§ 2-31, 7 U.S.C. §§ 136-136y (1988).
29. TSCA §§ 2-309, 15 U.S.C. §§ 2601-2671 (1988).
30. Coordinated Framework, 51 Fed. Reg. 23,302, 23,315.
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In 1989, the BSCC established a working group to resolve
the scope issue.81 This group developed several possible ap-
proaches, but was unable to reach a consensus on an appropri-
ate definition.32 One of the better scope definitions extended
regulatory oversight to "organisms deliberately modified by
the introduction into or manipulation of genetic material in
their genomes [and also exempted from oversight] five catego-
ries of modifications . . . from the total set of such orga-
nisms.""3 This definition was brought before the full BSCC,
which was similarly unable to reach a consensus, 4 but which,
nonetheless, forwarded the definition to the OSTP.3 5 Claiming
that the scope issue had policy implications beyond the juris-
diction of the BSCC, the OSTP forwarded the document to
The President's Council on Competitiveness." The Council on
Competitiveness' review produced a proposed scope definition
31. Proposed Oversight, 55 Fed. Reg. 31,118, 31,119.
32. Id.
33. Id.
34. Id.
35. Proposed Oversight, 55 Fed. Reg. 31,118, 31,119-20.
36. Id. at 31,120. Presumably the OSTP was concerned that over-regulation
might hinder the domestic biotechnology industry. The Council on Competitiveness
was created by President Bush on March 31, 1989. As the name suggests, the Coun-
cil's mission is to help U.S. industry by combatting what President Bush character-
ized as "the scourge of unnecessary regulation." Kirk Victor, Quayle's Quiet Coup, 23
NAT'L J. 1676 (1991). The Council often accomplishes this by reviewing - and per-
haps rejecting - proposed agency regulations. For instance, on April 6, 1991, the
Council issued a major rewrite of the EPA's regulations promulgated under the 1990
Clean Air Act Amendments, making them significantly weaker. See Nancy Shute,
Unfair Competition, THE AMicus J., Summer 1991 at 33. The Council is also reported
to have influenced the FDA's recently announced "hands-off" policy on the market-
ing of genetically engineered foods. See Warren E. Leary, Gene-Altered Food Held by
the FDA to Pose Little Risk, N.Y. TIMEs, May 26, 1992, at Al. In such actions the
Council's primary analytic tool is the application of cost-benefit analysis to proposed
regulations; this is a strategy dating to President Reagan's Executive Order 12291 of
February 17, 1981, which required agencies to do cost-benefit reviews of their own
regulations, and which created the Council's predecessor, the Task Force on Regula-
tory Review.
Although this Article does not purport to criticize the Council directly, the Fed-
eral Oversight document, authored largely by the Council, can be read as a virtual
laundry list of its favored methods: the application of cost-benefit analysis to regula-
tions which ought to have numerous goals other than efficiency, the heavy reliance on
quantitative risk analysis in situations where many of the risks are difficult to quan-
tify, and the exclusion of public input into the regulatory process.
1992]
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that the OSTP published in July, 1990 entitled, "Priipciples
for Federal Oversight of Biotechnology: Planned Introduction
into the Environment of Organisms with Modified Hereditary
Traits [the "Proposed Oversight document"]. ' 7 The proposal
submitted by the BSCC to the OSTP had been significantly
altered by the Council on Competitiveness. For instance, the
Proposed Oversight document took as its major goal the iden-
tification of categories of organisms that would be exempt
from federal oversight." Although this may at first seem like a
superficial jurisdictional maneuver, it actually goes to the core
of the substantive principles for regulation of biotechnology.
The principles used in classifying organisms as subject or not
subject to oversight are the same as the principles used to
evaluate the relative risk of those same organisms.39
In February of 1992, the Administration published its fi-
nal statement on the scope issue in the Federal Oversight doc-
ument."0 This final statement differs from the earlier Pro-
posed Oversight document primarily in that it no longer
mentions specific categories of organisms that would likely be
exempt from federal oversight, thus giving agencies more free-
dom to make their own determinations on this issue.' 1 On the
other hand, the Federal Oversight document advances a more
stringent concept of risk management. 2 Agencies are to exer-
cise oversight authority only to the extent that it is cost
effective.'3
In skeletal terms, the Federal Oversight document can be
summarized as follows. The document first suggests a method
for deciding which organisms should be subject to oversight -
only those that pose "unreasonable" risks." Next, the docu-
ment suggests a particular method for assessing the risks of
37. Proposed Oversight, 55 Fed. Reg. at 31,120-21.
38. Id. at 31,120.
39. See NATIONAL RESEARCH COUNCIL, FRAMEWORK FOR DECISIONS, supra note 9
(report from which the proposed oversight document draws these principles).
40. Federal Oversight, 57 Fed. Reg. 6753.
41. Id. at 6758-59.
42. Id. at 6757.
43. Id.
44. Id. at 6753. "Reasonableness" is defined in cost-effective terms; hence a level
of oversight whose costs are greater than its benefits is "unreasonable." Id.
[Vol. 10
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genetically modified organisms - determining their compara-
bility, in terms of a specified set of characteristics, to previ-
ously released, safe organisms."' Finally, the document recom-
mends that this methodology be used to choose, in particular
cases, the appropriate level of oversight."6 Further analysis of
the Federal Oversight document yields four foundation
propositions:
1. Biotechnology regulation should focus on the product
organism, not the process by which it was created.
2. Biotechnology regulation should be risk-based; over-
sight should be exercised at a given level of risk only to
the extent a net social benefit is realized.
3. The basis for biotechnology risk assessment should be
an organism's familiarity.'"
4. Principles 1-3 can be used to generate categories of or-
ganisms exempt from federal oversight.' s
The first three propositions are interrelated and support pro-
position four, which is the "bottom line" of the Federal Over-
sight document.
III. Critique of the Federal Oversight Document
This section of the article will examine the Federal Over-
sight document's four propositions. It will begin by reviewing
the development of "product over process" as the basis for
regulation." Next will be an examination of how an organ-
ism's perceived risk is used as the basis for regulation."0 Then
45. Id. Although the document phrases this method as a recommendation, and
acknowledges the availability of alternative methods, it does not name or describe
any alternatives.
46. Id. See Proposed Principles, 55 Fed. Reg. 31,118, 31,119.
47. 57 Fed. Reg. 6753, 6756. Technically, what is meant by the concept of famili-
arity is not just the organism itself, but the "introduction" as a whole. Thus factors
such as the environment into which the organism is introduced and the potential for
confining the organism once released are taken into account. Proposed Principals, 55
Fed. Reg. 31,118, 31,119.
48. 57 Fed. Reg. 6753, 6756. See 55 Fed. Reg. 31,118, 31,120.
49. For a discussion of product over process, see infra notes 53-73 and accompa-
nying text.
50. For a discussion of risk based regulation, see infra notes 74-113 and accom-
1992]
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there will be a review of the methodology under which an or-
ganism's familiarity - comparing its risk to that of an organ-
ism previously released - is used to determine the organism's
risk. 1 Finally, there will be an examination of the category-
based approach to regulation under which groups of similar
organisms were excluded from regulation.52
A. Product over Process as the Basis for Regulation
1. Development of the Product/Process Debate
When the Coordinated Framework was announced in
1986, there was still some question as to whether recombinant
DNA techniques were per se risky.53 In 1984, the EPA pro-
posed a scope definition targeting recombinant organisms for
regulation under the pre-manufacturing clearance provisions
for "new" substances under the TSCA 4 As the EPA noted, in
1986, this proposal was criticized by many who "expressed
concern that the Agency was relating a microorganism's po-
tential for risk to the process by which it was made." 5 Al-
though the EPA modified its scope definition in 1986 to in-
clude pathogens and organisms with "new combinations of
traits,"'  the latter provision was still essentially process-
based. It focused on the novelty of combinations achievable
with recombinant-DNA (hereinafter R-DNA) techniques,
rather than on their risk.
In 1987 the National Academy of Sciences (NAS) pub-
lished an influential report entitled, "Introduction of Recom-
binant DNA-Engineered Organisms in the Environment: Key
Issues. '5 7  The Academy's primary conclusion was that
panying text.
51. For a discussion of familiarity as a method of risk assessment, see infra notes
114-30 and accompanying text.
52. See infra notes 131-50 and accompanying text.
53. Coordinated Framework, 51 Fed. Reg. 23,302, 23,302-03.
54. Proposed Policy Regarding Certain Microbial Products, 49 Fed. Reg. 50,880,
50,886-87; TSCA § 5, 15 U.S.C. § 2604 (1988).
55. Coordinated Framework, 51 Fed. Reg 23,302, 23,315.
56. Id.
57. COMMITTEE ON THE INTRODUCTION OF GENETICALLY ENGINEERED ORGANISMS
INTO THE ENVIRONMENT, COUNCIL OF THE NATIONAL ACADEMY OF SCIENCES, INTRODUC-
[Vol. 10
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"[a]ssessment of the risks of introducing R-DNA engineered
organisms into the environment should be based on the na-
ture of the organism ... not on the method by which it was
modified." '58 Two years later, the National Research Council
(NRC) published a report, "Field Testing Genetically Modi-
fied Organisms: A Framework for Decisions."" This report
also adopted the "product not process" formula as a "funda-
mental principle" guiding its deliberations.6 It concluded that
''no conceptual distinction exists between genetic modification
of plants and microorganisms by either classical methods or
by molecular techniques that modify DNA and transfer
genes."'"
These two reports became the intellectual touchstones for
the subsequent scope debate. In 1989, the BSCC working
group, charged with producing a new scope definition,
adopted the NRC's conclusions.2 The President's Council on
Competitiveness also adopted the "product over process" ap-
proach .6  The Proposed Oversight document took pains to
avoid "the incorrect implication that the use of any particular
genetic modification process per se makes a modified organ-
ism of greater risk .... Such a misconception could inadver-
tently tend to retard research and the beneficial development
of the biotechnology industry."'64 This principle is adopted by
the Federal Oversight document.65 Because it concludes that
R-DNA techniques are neither per se risky nor a proxy for
risk, the document provides that a given organism should be
subject to oversight solely on the basis of the characteristics of
the organism, not on the process by which it was made. 66
TION OF RECOMBINANT DNA-ENGINEERED ORGANISMS INTO THE ENVIRONMENT: KEY Is-
SUES (1987) (hereinafter NATIONAL ACADEMY OF SCIENCES, KEY ISSUES).
58. Id. at 7.
59. NATIONAL RESEARCH COUNCIL, FRAMEWORK FOR DECISIONS, supra note 9.
60. Id. at 2.
61. Id. at 14.
62. Proposed Oversight, 55 Fed. Reg. 31,118, 31,120.
63. COMPETITIVENESS COUNCIL, supra note 1, at 12.
64. Proposed Oversight, 55 Fed. Reg. 31,118, 31,120.
65. Federal Oversight, 57 Fed. Reg. 6753, 6755.
66. Id.
1992]
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2. Critique of the Product over Process Strategy
As a first point of critique, it should be understood that
the impetus behind the product over process strategy derives,
in part, from the jurisdictional arguments made by agencies in
order to protect their authority to regulate biotechnology
under existing statutes. In many areas, this authority is cer-
tain only within a delimited sphere, not necessarily reflecting
the best possible regulatory approach. Agencies must argue
that biotechnology is not a radically new or different technol-
ogy, and that biotechnology products are not dissimilar from
products covered by existing regulatory mandates. Under
TSCA, for instance, EPA's regulatory authority depends upon
characterizing genetically engineered organisms as "chemical
substances. ' '67 Similarly, most statutes under which biotech-
nology is regulated are written in a "product over process"
model. Such statutes are based on regulating chemicals irre-
spective of their mode of origin.
As a result, the decision to regulate biotechnology under
existing statutes strongly hinders any deviation from the
product over process model. If a government authority were to
claim in a policy statement that the process of genetic engi-
neering was a significant factor in regulating biotechnology, it
would in effect be saying that biotechnology regulation was to
proceed in a manner not envisioned by statute. Clearly, this
would undermine the authority of the agencies under existing
statutes. While the Supreme Court has held that agencies
would be unlikely to lose in a case challenging their authority
67. See TSCA §§ 2-3, 15 U.S.C. §§ 2601-02 (1988) (stating that purpose of Act is
to regulate "chemical substances and mixtures" and defining that term). From the
definition of "chemical substances" given in the Act, it seems clear that TSCA regula-
tion of living organisms was not envisioned by Congress.
See generally C. Robert Manor, Note, Living Organisms as Chemical Sub-
stances: The EPA's Biotechnology Policy Under the Toxic Substances Control Act, 3
RUTGERS COMPUTER & TECH. L.J. 409 (1987) (arguing that TSCA, in its current form,
is inappropriate for biotechnology regulation). This is significant because living orga-
nisms are incorporated into and processed by the environment in a different manner
than are chemicals, and therefore they present different types of risks.
See also Tiedje et al., supra note 6, at 305 (arguing that the risks of genetically
engineered organisms are fundamentally different from the risks of chemical
substances).
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to regulate biotechnology, 8 agencies acquire and maintain le-
gitimacy in many ways other than through the judiciary.
Therefore, the problem is that regulation of biotechnology is
developing in response to jurisdictional arguments that can be
made to protect and project agency authority instead of in re-
sponse to national policy considerations.
With this background in mind, the product over process
formula can be further examined. As previously noted, the
Proposed Oversight document asserted that the products of
R-DNA techniques are not per se risky. 9 When stated as an
abstract scientific principle this may be true, since it amounts
to no more than the plausible assertion that not all genetically
modified organisms pose risks greater than the risks of the
parent organisms from which they were derived.7 0 However,
the product over process formula has not been elaborated in
only, or even primarily, a scientific setting. Rather, it has been
used in the political context with full awareness of its conse-
quences for regulation. In that context it may be used, not
surprisingly, to assert much more than is scientifically justi-
fied. Most importantly, given the jurisdictional analysis
presented above, the product over process formula has been
used to claim that biotechnology does not require any unique
or new regulatory attention; that is, no attention beyond that
already provided under statutes enacted without biotechnol-
ogy in mind.71
The assertion that biotechnology requires no new regula-
68. See Chevron, U.S.A., Inc. v. Natural Resources Defense Council, Inc., 467
U.S. 837, 845 (1984). Under Chevron, Congress is not required to have spoken di-
rectly to the exact limits of a government agency's power. It is enough that the
agency's extension of its authority under the statute reflects a "reasonable" agency
construction of the statute's language and goals. Id.
69. Proposed Oversight, 55 Fed. Reg. 31,118, 31,120. See supra text accompany-
ing notes 53-66.
70. For example, many genetic modifications involve splicing small "markers"
into an organism's genome. In the majority of cases, such markers have no phenotypic
effects, and the resulting organism thus presents no greater risks than does the parent
strain. Similarly, genetic modification can just as easily make the resulting organism
less risky than the parent strain: a cholera bacterium with the "cholera toxin" gene
deleted is a good example.
71. Proposed Oversight, 55 Fed. Reg. 31,118-19.
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tory attention simply does not follow from the principle that
biotechnology is not per se risky. The fact that the process of
genetic engineering does not always produce risky organisms
does not imply that the risky organisms it does produce pre-
sent no new or unique types of risk. Thus, while genetically
modified organisms might not be per se risky, they might very
well have characteristics that make the risks they pose of a
sort not easily regulated by the current regimes.
Certain groups of scientists believe this theoretical analy-
sis can be complemented with empirical data suggesting that
genetically modified organisms pose novel risks. A scientific
working group has recently asserted that "[o]rganisms with
novel combinations of traits are more likely to play novel eco-
logical roles." 72 To assert this is hardly to prove it; but simply
establishing the existence of a valid theoretical controversy is
enough to make the political extension of the product over
process formula look less than principled.
This argument does not challenge the product over pro-
cess formula's scientific core. Rather, it challenges the politi-
cal overextension in the regulatory context. The formula
should instruct us that the process of genetic engineering is
not inherently dangerous; but from that we should not infer
that no new regulation is required. Instead, we should follow
the example of the Ecology Society of America which, while
accepting the product over process formula, cautions against
its overextension "because many novel combinations of
properties can be achieved only. by molecular and cellular
techniques, [and] products of these techniques may often be
subjected to greater scrutiny than the products of traditional
techniques. '7 3
B. Risk-Based Regulation
Along with the product over process formulation, the
72. Tiedje, et al., supra note 6, at 300. The specific kinds of risks the ESA has in
mind include long-term damage to ecosystems, cumulative and synergistic effects of
different strains of genetically engineered organisms, and pleiotropic effects. Id. at
304-05.
73. Id. at 310-11.
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Federal Oversight document adopts the proposition, first as-
serted in the Proposed Oversight document. 4 The President's
Council on Competitiveness has already endorsed the risk-
based approach in its "Report on National Biotechnology Pol-
icy,"17 and, beyond that, the concept connects to much
broader currents in regulatory theory. Throughout the 1980's,
risk assessment came to play a more significant role, especially
in the field of environmental regulation. The reasons for this
are varied. One commentator attributed the shift to theoreti-
cal factors, suggesting that "[a] liberal state attempts to main-
tain neutrality among competing conceptions of the good by
focusing on pragmatic considerations and that [e]xisting bio-
technology regulation, which has dealt almost entirely with
first-order physical effects, is firmly within this tradition." 6
But, the shift could also be the result of a new administrative
stance requiring agencies to base regulations on cost-benefit
analyses.7 Only a quantitative procedure, like risk assess-
ment, yields data that can be easily incorporated into a cost-
benefit calculation. From the Administration's perspective,
this legitimizes the regulation.78 Similarly, risk assessment
holds out the promise of "objective," scientific regulations,
regulations that are easier to defend and which, because they
tend to seem less directly political, are less likely to become
embroiled in political controversy.
74. Federal Oversight, 57 Fed. Reg. 6753, 6756. "The principles for scope are risk
based [and that] [o]versight is not required for planned introduction experiments un-
less information concerning the risk posed by the introduction indicates that over-
sight is necessary. Proposed Oversight, 55 Fed. Reg. 31,118, 31,120.
75. COMPETITIVENESS COUNCIL, supra note 1, at 11-15.
76. Richard B. Stewart, Regulatory Law, in THE GENETIC REVOLUTION 212, 233
(Bernard D. Davis ed., 1991).
77. Exec. Order No. 12,291, 3 C.F.R. § 127 (1981), reprinted in 5 U.S.C. § 601
(1988). Section 2(b)-(d) of the Order sets out the goal of balancing a regulation's
benefits with its costs. Id. Section 3(d) specifies the required elements of the "Regula-
tory Impact Analysis". Id.
78. It should be noted that under Section 3(d)(1)-(3) of Executive Order 12,291,
Regulatory Impact Analyses are permitted to take account of "effects that cannot be
quantified in monetary terms." Id. But the "bottom line" approach endorsed by the
Order makes it clear that unquantifiable risks, although they might enter into the
equation, will be effective only at the margins.
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1. Risk-Based Regulation of Biotechnology
These explanations suggest that the Administration fa-
vors risk assessments based upon "hard" and "first-order"
sources of risk. As Stewart notes, this has been the case in the
field of biotechnology regulation.7 9 Stewart's observation pro-
vides an explanation for the product over process formulation,
the narrow focus of current risk assessment considers only the
first-order risks of biotechnology products, and omits the
broader implications of the process by which they were cre-
ated. The product over process formulation, although it seems
to be a fundamental principle only within the confines of bio-
technology, is itself a product of a broader trend in contempo-
rary risk assessment.
One of the problems with this particular style of risk as-
sessment is its tendency to give more emphasis - although
admittedly not exclusive emphasis - to easily quantifiable
risks.80 This would be an acceptable approach if it were true
that easily quantifiable risks were either the only risks worth
regulating, or the risks of greatest magnitude. However, there
is no reason to believe that these conditions are satisfied.81 In
the field of environmental law, and especially in the area of
79. Stewart, supra note 76, at 212-13.
80. See John S. Applegate, Worst Things First: Risk, Information, and Regula-
tory Structure in Toxic Substances Control, 9 YALE J. ON REG. 277 (1992).
81. Proponents of quantitative risk assessment might also make an "economics
of information" argument here. Quantifying risks requires research to generate the
necessary information, which in turn requires more money. A cost/benefit analysis
would therefore seem to favor regulation of quantifiable risks, since the benefits
gained by regulating hard-to-quantify risks are lessened by the start-up costs of gen-
erating necessary information. See generally John S. Applegate, The Perils of Unrea-
sonable Risk: Information, Regulatory Policy, and Toxic Substances Control, 91
COLUM. L. REv. 261 (1991) (discussing economics of information in the regulatory
process).
This argument does indicate that a cost/benefit consideration of regulating hard-
to-quantify risks should take information costs into account, but it hardly amounts to
a proof that regulating easily quantifiable risks is always more efficient. Assuming
that both sets of risks have similar spectrums of possible marginal gains (e.g., from
efficient to inefficient regulated risks), it would always be the case that regulating
some of the hard-to-quantify risks would be more efficient than regulating only quan-
tifiable risks. Thus the information costs would in some cases be well-spent, as would
perhaps regulation even without the necessary information, if the risks involved seem
potentially very serious.
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biotechnology, many potential risks are accompanied by sub-
stantial uncertainty.8 2 Furthermore, when a risk involves long
term effects on complex ecosystems, quantitative assessment
can be speculative at best. Unfortunately, quantifiable risks
tend to be ignored under the present concept of risk-based
regulation.
Another general feature of risk assessment is its tendency
to make political or value decisions seem like objective scien-
tific conclusions."3 While this may be of strategic benefit to
agencies or elected officials, it has undemocratic implications.
Critics have recently advanced the thesis that, appearances to
the contrary, quantitative risk assessment is not merely a sci-
entific calculation. Rather, it involves significant value-based
decisions.8 " The thesis includes decisions about how to frame
problems, about what sorts of risks will be considered (e.g.,
aggregate cancers or deaths versus cancer or death rate among
maximally affected population), and about which baselines
will be used (e.g., how much risk is "acceptable").
The baseline problem is particularly important when a
risk assessment is combined with a cost-benefit analysis in
formulating a regulation. However, since no satisfactory the-
ory exists for determining a."rational" degree of risk aversion
or risk taking, such decisions are often subjective." Further, a
82. See generally Howard Latin, Good Science, Bad Regulation, and Toxic Risk
Assessment, 5 YALE J. ON REG. 89, 102-03 (1988); see also Note, The EPA and Bio-
technology Regulation: Coping with Scientific Uncertainty, 95 YALE L.J. 553 (1986).
83. See Latin, supra note 82, at 92-94.
84. See, e.g., NATIONAL RESEARCH COUNCIL, RISK ASSESSMENT IN THE FEDERAL
GOVERNMENT: MANAGING THE PROCESS 28 (1983) (acknowledging that risk assessments
always include policy judgments and should therefore not be left to politically unac-
countable bodies).
85. For example, if a person is offered a 75% chance at a lifetime income against
a 25% chance of losing everything, utility analysis suggests that all but the most aged
and wealthy should take the chance. Analogously, a risk assessment combined with a
cost/benefit analysis would make a similar recommendation in the case of uncertain
technologies such as nuclear power, where a small chance of catastrophic loss must be
balanced against great social gains. But, in either of these cases, it is just as rational
to avoid taking such a chance, for fear of the small chance of catastrophic loss. Of
course, one might influence the risk until the risk was so small and/or the benefit so
great, that the vast majority of people would take the risk - or one might vary the
risk in the opposite direction.
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wide spectrum of rational levels of risk aversion exists, thus
implicating the need for political decisions.
Although science can help frame issues, it should not
make political choices. While quantitative risk assessment is a
valuable scientific aid in regulatory decision-making, it should
not be given an "objective" or "neutral" status and be allowed
to substitute for the political process. In the area of biotech-
nology, which evokes many fundamental social values, a
purely technocratic solution is singularly inappropriate.
Proponents of quantitative risk assessment are aware of
this issue. The NRC acknowledges that within any risk assess-
ment, "a number of decision points occur where risk to human
health can only be inferred... [and that b]oth scientific judg-
ments and policy choices may be involved in selecting from
among possible inferential bridges.""6 Generally, attempts to
address this problem have adopted the NRC's suggestion to
differentiate between "risk assessment" and "risk manage-
ment. ' 87 These two regimes are differentiated by the regula-
tory equivalent of the philosophical "fact/value" distinction. 8
That is, risk assessment is supposed to be based on objective,
factual questions like "how much risk does chemical x pre-
sent;" whereas risk management is guided by value judgments
such as "we do/do not want to live with the level of risk
presented by chemical x." But, just as contemporary philoso-
phers question fact/value distinctions, we should question the
validity of splitting regulation into risk assessment and risk
management.8 9 First, while this distinction might alleviate the
86. Id. at 3.
87. Id. This approach was quickly embraced by the EPA. See William D. Ruck-
elshaus, Risk in a Free Society, 14 ENVTL. L. REP. (Envtl. L. Inst.) 10,190 (May 1984);
U.S. EPA, FRAMEWORK FOR THE FUTURE: RISK ASSESSMENT AND RISK MANAGEMENT AT
EPA (1984).
88. The fact/value distinction, like the risk assessment/management distinction,
seeks to distinguish an objective, rationally knowable realm from a subjective realm
of contingent human values. The distinction was a favorite of a group of philosophers
known as logical positivists. See, e.g., ALFRED JULES AYER, LANGUAGE, TRUTH, AND
LOGIC (1952).
89. See Milton Russell & Michael Gruber, Risk Assessment in Environmental
Policy-Making, 236 Sci. 286, 286 (1987) (claiming that the distinction between risk
assessment and risk management falters because there is "no 'bright line' between the
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baseline problem discussed above (now seen as a problem of
risk management rather than assessment), it does not solve
the problems raised by risk assessment's need (1) to frame its
problems, (2) to decide which aspects of which risks are to be
assessed, and (3) to make intermediate "scientific" choices
among pessimistic and optimistic models for variables (such
as dose-response and exposure level).90 Second, risk manage-
ment is increasingly dominated by "comparative risk analy-
sis," which also has been faulted for ignoring important value
choices, 1 and by cost-benefit analysis. Both of these tech-
niques may merely recreate the science/policy problem at a
higher level.
A related problem with the Administration's current style
of risk assessment is its mistrust of the public's risk percep-
tions. For example, academic supporters of risk analysis have
developed theories relating to faulty risk perceptions among
average people under names such as "cognitive error the-
ory."92 This intellectual movement has had wide-ranging ef-
fects. Most recently, in 1991, EPA Administrator William
Reilly unveiled a new Agency effort to base regulatory deci-
sions on "the scientific understanding of risk" rather than on
"public risk perceptions." 8 His statement was backed by a re-
policy considerations inherent in risk management and those inherent in risk
assessment").
90. See Risk Assessment Guidelines Released by EPA after Prefatory State-
ment is Added for OMB, 17 Env't Rep. (BNA) No. 18, at 627 (Aug. 29, 1986), discuss-
ing comments made in a letter by Wendy L. Gramm, OMB Administrator of Informa-
tion and Regulatory Affairs, Letter of Aug. 12, 1986, to Lee M. Thomas, EPA
Administrator. Gramm criticized the EPA's cancer risk assessment guidelines on the
ground that "[t]he real risk management decision will not be made by regulatory
officials, but instead by those involved in the risk assessment process who determine
which data to use, which of several scientifically valid models to employ, and which
information to reveal." Id.
91. See, e.g., Donald Hornstein, Reclaiming Environmental Law: A Normative
Critique of Comparative Risk Analysis, 92 COLUM. L. REV. 562, 592-93 (1992).
92. See, e.g., Amos Tversky & Daniel Kahneman, Judgmnent under Uncertainty:
Heuristics and Biases in JUDGEMENT UNDER UNCERTAINTY 3 (Daniel Kahneman, Paul
Slovic, & Amos Tversky eds., 1982). For an excellent discussion of the use of cognitive
error theory in risk assessment, see Hornstein, supra note 91, at 604-16.
93. Report of the EPA's Science Advisory Board: Hearing before the Sen.
Comm. on Env't and Pub. Works, 102d Cong., 1st Sess. 45 (1991) (statement of Wil-
liam K. Reilly, Adm'r, EPA).
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port by the EPA's Science Advisory Board (SAB),9' which as-
serted the need to "improve the public's understanding of the
scientific and technical aspects of environmental risk."' 5 The
report left room for considering the public's "deeply held sub-
jective values, like justice and equity,"' a point not dwelt
upon by the Administration. Since that statement, however,
the Administration has moved even further from the SAB's
advice. The Office of Management and Budget (OMB), for ex-
ample, has recently moved to make comparative risk analysis
the first principle of environmental regulation, 7 a move which
would reduce the need for public input even further.'
Advocates of risk assessment question the validity of pub-
lic perceptions, because they believe that the public takes ir-
relevant factors into account when making risk decisions. The
basis of the public's misconceptions is generally believed to be
in the use of misleading "heuristics." '" In the face of scientific
uncertainty, such heuristics, often reflecting deeply held val-
ues, deserve more credit. 100 In the case of the environmental
release of genetically modified organisms, this is especially
true because, due to the infancy of the field and to the conse-
quent lack of negative examples (e.g., Chernobyl), risk assess-
ment is particularly speculative. The public's use of "dread
risk"101 as a decision-making factor is thus not prima facie ir-
rational. Aspects such as the irreversible or catastrophic po-
tential of a risk, or its consequences for future generations, or
the voluntary nature of risk-bearing, are indeed worthy of
94. EPA, SCIENCE ADVISORY BOARD, REDUCING RISK: SETTING PRIORITIES AND
STRATEGIES FOR ENVIRONMENTAL PROTECTION (1990).
95. Id. at 12.
96. Id.
97. Risk Reduction Initiative in 1992 Proposal Targets DoE, DoD, EPA Envi-
ronmental Program, 21 Env't Rep. (BNA) 1791, 1796-97 (Feb. 8, 1991).
98. See generally Hornstein, supra note 91, at 604-05 (describing this trend in
EPA's view of public risk perceptions).
99. Heuristics are "usually speculative formulations serving as a guide in the in-
vestigation or solution of a problem." THE AMERICAN HERITAGE DICTIONARY 610 (2d
College ed. 1982).
100. Hornstein, supra note 91, at 604-05.
101. Paul Slovic, Perception of Risk, 236 Sci. 280, 283 (1987).
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consideration by regulatory bodies. 102
Even if the public's risk perceptions are inaccurate, the
Administration's approach is strategically poor, and likely to
be perceived as undemocratic in the sense that the public is
excluded from decision making. Also, in the absence of mas-
sive education efforts, the public is unlikely to adopt the Ad-
ministration's "scientific" perspective. Thus, the Administra-
tion might enter a circle in which administrative "objectivity"
engenders increasing public mistrust. For biotechnology, this
result is especially likely to occur for two reasons. First, the
public might perceive that those who stand to gain most from
biotechnology - scientists and industry specialists - as be-
ing those who are the most deeply involved in the purportedly
objective risk assessment process. Second, in taking decisions
further from the public, the Administration will only accentu-
ate the anxiety that naturally results from a perception of risk
and a feeling of impotence.
In conclusion, risk-based regulation in the biotechnology
context has two strikes against it. First, it fails to take fully
into account significant dangers because they are hard to
quantify, or because they fall outside its narrow framing pro-
cedures. For a new technology like biotechnology, and for one
whose risks are likely to be complex, long-term, and synergis-
tic, it is very likely that quantitative risk assessment will un-
derestimate the actual risks. Second, it fails to take public
perceptions of risk into account, assuming instead an increas-
ingly adversarial stance toward public perceptions. As Latin
notes, in a situation where "good science" is not to be had, a
more openly political choice is required, one that should at
least balance quantitative risk assessment with public
perceptions. 10 3
Making quantitative risk assessment the sole basis for
biotechnology regulation makes neither practical nor political
sense. A regulatory regime built on this approach is likely to
increase public anxiety, mask important political choices in
purportedly neutral, scientific terms and ultimately, fail to
102. Hornstein, supra note 91.
103. Latin, supra note 82, at 148.
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consider many of the potential hazards presented by
biotechnology.
2. The Risk-Based Approach in the Federal Oversight
Document
Having discussed the use of risk-based regulation on bio-
technology generally, it is also necessary to turn to the Fed-
eral Oversight's specific deployment of this approach. This is
expressed in the following principle: "[a] determination to ex-
ercise oversight in the scope of discretion afforded by statute
should be based on evidence that the risk presented by intro-
duction of an organism ... is unreasonable.""1 4 Two features
differentiate this principle from the approach utilized in the
Oversight Principles. First, agencies only act to minimize risks
that are unreasonable. The Federal Oversight defines a risk as
unreasonable if its cost to society is greater than the cost of
regulating it, and thus introduces a cost-benefit analysis into
oversight decisions.10 5
While this represents a refinement of the Proposed Over-
sight document, in the sense of recognizing that agencies have
more complex alternatives than a binary choice between regu-
lating and not regulating, it also exceeds the Proposed Over-
sight document in the sense of no longer being primarily
about scope. Using the "reasonable" standard, the Federal
Oversight document constitutes a substantive guide to agency
standard setting (presumptively, of course, within the limits
of statutory authority). The Federal Oversight document as-
serts that the "unreasonable risk" definition "enables, and re-
quires, agencies to choose from among the range of oversight
options those measures that obtain net benefits."1 6
One problem with the Federal Oversight document's
more aggressive approach is that agencies regulating risks
under various statutes typically already have threshold stan-
dards for regulation, many of which are prescribed by statute.
104. Federal Oversight, 57 Fed. Reg. 6753, 6756.
105. Id. (agencies must choose regulatory strategies which achieve risk reduction
at net benefit and least cost).
106. Id. at 6757.
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While it may be true, as the Federal Oversight document as-
serts, that "'unreasonable risk' is already a criterion used by
federal agencies, such as in exercising oversight under provi-
sions of TSCA and FIFRA," this ignores the fact that the use
of "unreasonable" in such statutes has usually not been con-
strued to mean the narrow cost-benefit interpretation advo-
cated by the Administration. 107 Although the costs of regula-
tions are often included among the factors to be taken into
account, they are seldom the sole or controlling factors.
Thus, the mandates of the Federal Oversight document
will present agencies with a serious problem: reconciling the
statutory thresholds for oversight with those advanced by the
Federal Oversight document.108 Indeed, to the extent it would
not directly violate the "within statutory limits" provision,
adopting the Administration's "reasonable" standard might
result in biotechnology products being regulated less strin-
gently than conventional products (for which the cost-benefit
analysis is only one factor among many).
The second major problem with the Federal Oversight
document's definition of unreasonable risk is that it exacer-
bates a negative feature of quantitative risk assessment gener-
ally: the devaluing of hard to quantify risks - risks that may
be particularly relevant in the context of biotechnology. 10 9 In
the previous section, it was shown how quantitative risk as-
sessment tends to underemphasize risks that are not currently
well understood, that are cumulative or synergistic, and that
take a long time to surface."'
Adding a cost-benefit approach to quantitative risk as-
sessment magnifies the problem because of an imbalance be-
tween the ease of determining costs and benefits. Filling out
the "benefits of regulation" side of the equation requires
107. See Applegate, Worst Things First, supra note 80, at 295.
108. This problem was avoided by the Proposed Oversight document which,
while being risk based, nonetheless left the determination of the threshold level of
risk up to agencies. Proposed Oversight, 55 Fed. Reg. 31,118, 31,120. "Oversight is not
required . . . unless information concerning the risk posed by an introduction indi-
cates that oversight is necessary." Id.
109. See supra text accompanying notes 80-82.
110. See supra text accompanying notes 79-103.
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quantifying the risks avoided, as well as a process of valuing
the environment, a process that raises a number of difficult
problems.' In contrast to the difficulty of quantifying the
"benefits" side of the equation, the "costs of regulation" side
can be easily quantified as involving the loss of jobs, costs to
firms, and administrative costs. Thus, the cost-benefit analysis
is likely to devalue the risks involved with biotechnology. This
is particularly true when one reflects that uncertain numbers
may be more easily manipulated according to underlying val-
ues. If the agencies accept the values of the Federal Oversight
document, any uncertainty in the calculation of the benefits of
regulation will be resolved by choosing the minimum figure.
In attempting to deal with the information costs of regu-
lation, the Federal Oversight document suggests that the un-
certainty of risks weighs against regulation. The document
does this by specifying that "[any information requests
should be designed to maximize their benefits and minimize
their costs by soliciting only the most useful information in
the least costly manner."'1 2 Because the information gathered
on an organism is used to determine the organism's risk, the
quantity and quality of such information has a bearing on reg-
ulatory decisions. A decision based on cost-effectiveness may
limit the information gathered on an organism. Then, on the
basis of such limited information, an organism may be
deemed to pose a reasonable risk that does not call for regula-
tion. But, while information costs are clearly an important
factor, it is not clear that such costs should always be a disin-
centive for regulation.
Consider the case of toxic tort litigation." 3 In these cases,
111. See Ohio v. United States Dep't of Interior, 880 F.2d 432, 438-50 (D.C. Cir.
1989) (discussing alternative methods for valuing harm to natural resources under the
Comprehensive Environmental Response, Compensation and Liability Act of 1980
(CERCLA), 42 U.S.C. § 9651(c)); see also Frederick R. Anderson, Natural Resource
Damages, Superfund, and the Courts, 16 B.C. ENVTL. AFF. L. REV. 405 (1989).
112. Federal Oversight, 57 Fed. Reg. 6753, 6757. The document also notes that
"[i]f the risk reduction to be gained is small, as will usually be the case with low-level
risks, less costly oversight options will need not apply." Id.
113. See, e.g., In re "Agent Orange" Prod. Liab. Litig., 611 F. Supp. 1223
(E.D.N.Y. 1985), afj'd, 818 F.2d 187 (2d Cir. 1987), cert. denied, 487 U.S. 1234 (1988);
Jackson v. Johns-Manville Sales Corp., 750 F.2d 1314 (5th Cir. 1985), cert. denied,
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issues of causation are generally very complex, and weigh
against the plaintiffs. We often know in an extrajudicial way
that some harm was done, but the scientific evidence does not
always live up to the burden established by legal rules. In
such cases, imposing high standards of proof has the effect of
forcing plaintiffs to bear the information costs. This, in turn,
may make it not worth their while to sue. Such a situation
may create poor incentive effects, since firms will realize they
are at no risk of being held liable, whatever their behavior.
Thus the net social result of imposing information costs on
the plaintiffs may be negative. In the case of biotechnology,
similar concerns must be addressed. Firms should not receive
a regulatory subsidy simply because the risks of their prod-
ucts are difficult to precisely determine. A more reasoned ap-
proach would be to ask them to participate in generating in-
formation needed for accurate regulation.
In conclusion, the "unreasonable risk" threshold for
agency oversight is flawed in two respects. First, it promises to
be difficult to reconcile with threshold standards already in
place under various statutes. Second, because the costs of reg-
ulation can be more easily quantified than can the benefits,
the approach will tend to exacerbate the bias toward under-
regulation already present in quantitative risk assessment.
These flaws are particularly evident in the case of biotechnol-
ogy regulation because of the higher degree of uncertainty
concerning the risks of genetically modified organisms.
C. Familiarity as a Basis for Risk Assessment
Having established that the scope of biotechnology over-
sight will be determined by a risk-based evaluation of biotech-
nology's products, the Federal Oversight document presents a
method for performing the actual risk analysis: "One means of
judging the risk posed by an introduction is to compare its
risk to an introduction of a comparable organism ... previ-
ously used in introductions in a comparable target environ-
478 U.S. 1022 (1986).
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ment." 1 4 The "comparable organisms" strategy reflects the
influence of the NRC report, "Field Testing Genetically Modi-
fied Organisms: Framework for Decisions," which identifies an
organism's "familiarity" as the key factor in assessing its
risks.11 5 Specifically, the proposed framework for decisions
specifies three basic questions, ordered as a flow chart such
that a "yes" to each question means no regulation is required;
whereas, a "no" entails asking the next question. The first
question is "are we familiar with the properties of the organ-
ism and the environment into which it will be introduced?"""
The familiarity standard has certain advantages. As the
report notes, "[i]ts use permits decisionmakers to draw on
past experience with the introduction of plants and microor-
ganisms into the environment, and it provides future flexibil-
ity ... as our knowledge increases, entire classes of introduc-
tions may become familiar enough to require minimal
oversight. 11 7 Additionally, use of the familiarity standard
complements the product over process formula in defending
the proposition that there is nothing new about genetically
modified organisms. As the Federal Oversight document
notes, "[a]n organism can be similar to a previously used or-
ganism regardless of the process by which the organism has
been modified." 18
But by the same token, this latter statement demon-
strates the familiarity approach's reliance on the two princi-
ples criticized above. If one questions the appropriateness of
the administration's narrow concept of "risk-based regula-
tion," and consequently questions the decision to consider
only the products of biotechnology and not the process of
manufacture, then the familiarity standard appears to rest on
shaky ground. Perhaps the familiarity approach is, like the
other two principles, the result of a limited regulatory focus
that overlooks the broader implications of the new technology,
114. Federal Oversight, 57 Fed. Reg. 6753, 6757.
115. NATIONAL RESEARCH COUNCIL, FRAMEWORK FOR DECISIONS, supra note 9, at
5.
116. Id.
117. Id.
118. Federal Oversight, 57 Fed. Reg. 6753, 6757.
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that makes important political decisions look like value-neu-
tral science, and that fails to consider public perceptions.
1. Problems with the Familiarity Strategy
The surprising thing about the familiarity approach is
that it not really a method of risk assessment at all, but rather
an exhortation to compare risk assessments presumably al-
ready made. This lends it an air of circularity. On the one
hand, the Federal Oversight document suggests that an organ-
ism's risk should be judged by comparing it to similar orga-
nisms, while, on the other hand, the notion of "comparable" is
itself risk based.11 ' In practice, this approach is likely to lead
to the replacement of regulation by risk assessment with regu-
lation by analogy. The result is likely to resemble the chil-
dren's "rumor" game, where a spoken message is whispered
from ear to ear around a circle: each child passes on a message
"comparable" to the one she heard, but the end result is often
a completely new creation - or to return to our subject mat-
ter, a completely new level of acceptable risk.
The concept of familiarity also hides two examples of "ar-
bitrary baselines."1 12  According to Donald Hornstein,
"[b]aselines are framing devices that make all the difference
in the way society evaluates the acceptability of risk. Yet...
comparative risk analysts . .. imply an ability to locate the
risk baseline in a neutral and sensible manner."12' The first
baseline decision regarding familiarity involves the question:
119. Id. at 6753, 6757-58. This can be seen in the document's phrase, "introduc-
tion posing comparable risk to a previous introduction." Id. This circularity was also
present in the Proposed Oversight document. There, risk was to be determined on the
basis of an organism's "similarity" to previously introduced organisms. But the docu-
ment went on to say, "an introduction is considered similar. . . when the level of risk
of the introduction is the same as or less than a previous introduction." Proposed
Oversight, 55 Fed. Reg. 31,118, 31,120. The Federal Oversight document mentions
that some public commentators had pointed to the "potential circularity" in the Pro-
posed Oversight document, Federal Oversight, 57 Fed. Reg. 6753, 6757, and this is
presumably why the term "similar" was replaced by "comparable." The circularity,
however, remains.
120. Hornstein, supra note 91, at 618.
121. Id. (discussing the way baseline decisions are often hidden with the objec-
tive language of risk analysis).
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How similar does an organism have to be to a previously re-
leased "comparable" organism? The "Framework for Deci-
sions" report cautions in its analysis that "terms such as 'un-
certainty,' 'sufficient,' and 'significant' are used in the
framework without precisely defining their quantitative limits.
Any specific numerical values assigned would be arbitrary and
subject to disagreement, as some underlying variables may be
difficult to quantify precisely.' 12 2 But these are, of course,
terms that are central to the determination of an organism's
"familiarity." The report also states that, because these terms
cannot be quantified precisely, "assignment of risk categories
must include a rational examination of the relevant scientific
knowledge for each introduction."1 " ' But, scientific knowledge
is not what is needed to solve the baseline problem. Questions
about, (1) how much "uncertainty" is acceptable, (2) which
aspects of an organism are "significant," and (3) how closely
related two organisms must be to be considered "similar," all
involve value decisions that cannot be resolved by scientific
knowledge alone.
This analysis must be applied specifically to the Federal
Oversight document. Consider its clear statement of the fa-
miliarity-based method: "An introduction should be subject to
no greater degree of oversight than was a comparable organ-
ism or product previously used in past safe introductions in a
comparable target environment.' 2' This principle is meant to
apply in cases where the previous introduction involved a
non-genetically-modified organism and the current introduc-
tion involves a modified one. As to their relative risks, regula-
tors are to follow the principle that "[modified] organisms ...
conferring no greater risk to the target environment . .
should be subject to a level of oversight no greater than that
associated with the unmodified organisms." 5 Note that given
the analysis above, the phrase "conferring no greater risk" is
122. NATIONAL RESEARCH COUNCIL, FRAMEWORK FOR DECISIONS, supra note 9, at
125.
123. Id.
124. Federal Oversight, 57 Fed. Reg. 6753, 6757.
125. Id. at 6756.
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imprecise. Because the determination is based on the methods
of quantitative risk assessment criticized above, it will under-
estimate the cumulative and long term risks that may result
from novel organisms." The comparability determination,
employed within the framework suggested by the Federal
Oversight document, is likely to have a systematic bias that
would tend in the direction of allowing ever more risky orga-
nisms to avoid federal oversight.
The familiarity approach presented in the Federal Over-
sight document would exempt from oversight those organisms
that are similar to organisms used in previous "safe" introduc-
tions. The second baseline problem derives from the question
concerning just how safe the past introductions need be. Al-
though they may all have been classified "safe," there will be,
nonetheless, significant differences of absolute risk among
them. In linking oversight of genetically modified organisms
to the "safety" of previously unregulated releases, the Federal
Oversight document's approach avoids the basic question of
how much risk society is willing to accept from biotechnology.
For instance, because of the newness and uncertainty of bio-
technology's risks, it might be decided that a higher standard
is appropriate and that new introductions need to be similar
not just to previous "safe" introductions, but rather to past
"extremely safe" introductions.1 2 7 The Federal Oversight doc-
ument's "comparable organism" method of risk assessment
hides the fact that the decision concerning the appropriate
definition of "safety" is a political question, not a scientific
one. A final problem is that the Federal Oversight document
does not clarify how the safety of previous releases should be
determined. Is it enough that releases of a given organism
have not yet led to serious problems, or is a more exhaustive
risk analysis necessary? Considering the complexity of ecosys-
126. Cf. Tiedje, et al., supra note 6, at 300. "[N]ovel organisms with novel combi-
nation of traits are more likely to play novel ecological roles, on average, than are
organisms produced by recombining genetic information existing within a single evo-
lutionary lineage". Id.
•127. This theme will be taken up in the discussion of the "ample margin of
safety" requirement of many statutes dealing with toxins, and its relevance to bio-
technology regulation. See infra notes 156-57 and accompanying text.
1992]
31
258 PACE ENVIRONMENTAL LAW REVIEW
tems, coupled with the fact that environmental risks often de-
velop very slowly and are difficult to detect, this is an issue
that warrants more consideration than it is given by the Fed-
eral Oversight document.2 8
2. The German Approach to Familiarity
It is instructive to contrast the Federal Oversight Docu-
ment's familiarity approach with biotechnology regulation in
Germany. Whereas the American approach seems to be built
around the central idea that genetically modified organisms
are not new, and are for the most part familiar, the German
Parliament seriously considered the idea that biotechnology
presents a radically new regulatory challenge.'29 The Parlia-
ment was pushed to draft a law on biotechnology regulation
when an administrative court held that the regulatory agency
charged with granting permits to biotechnology processing
plants had no authority to do so under existing statutes. 30
The court reasoned that the types of risk presented by the
release of genetically engineered organisms were fundamen-
tally new in kind and, since existing statutes therefore did not
envision them, the agencies deriving authority from these
statutes had no authority to regulate biotechnology. A new
legislative norm was required. This ruling prompted the Ad-
ministration to propose a comprehensive law for the regula-
tion of genetically engineered organisms. After broad, lengthy
debate and extensive amendment, the "Gentechnikgesetz"
was enacted in March of 1990.
The German experience should make one reconsider the
128. Cf. Tiedje, et al., supra note 6, at 305 (discussing the difficulty of accurately
determining the safety of a given release, and concluding with respect to the temporal
dimension of risk that "the absence of an immediate negative effect does not ensure
that no effect will ever occur").
129. The American view is based on our overextension of the product/process
formula, discussed supra notes 53-73 and accompanying text.
130. Judgement of Nov. 7, 1989, Hessischer Verwaltungsgerichtshof, 8 TH G85/
89, Administrative Court of Hessen. Generally speaking, German courts require that
legislative delegations of authority to executive agencies be more specific and concrete
than American courts do of congressional delegations. See generally RONALD BBUcK-
MAN, aT AL., CONTROLLING CHEMICALS 100-28 (1985) (describing different regulatory
role of courts in the United States, Germany, Great Britain and France).
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easy use of "familiarity" in the Federal Oversight document.
In addition to the arguments presented in this section, it sug-
gests that even if one does accept the model of risk-based reg-
ulation for the environmental release of genetically engineered
organisms, the "familiarity" approach recommended by the
Federal Oversight document would leave important factors
out of the risk equation. Indeed, since we have chosen once
already to de-emphasize biotechnology's unique aspects - by
regulating it under statutes not enacted with it in mind - the
risk assessment methods used in its regulation should, unlike
the familiarity approach, ensure that they are considered.
D. The Category-Based Approach to Biotechnology
Regulation
After elaborating a method of risk assessment similar to
that developed in the Coordinated Framework document, the
tentative Oversight Principles document concluded with a list
of "categories of organisms that would generally be excluded
from [federal] oversight." 1 As one of the Proposed Oversight
document's most controversial features, this list of exemption
categories drew a good deal of public comment. As a result,
the Federal Oversight document dropped this approach, citing
two reasons." 2 First, the categories given in the Proposed
Oversight document were not based on specific risk justifica-
tions made under particular statutes (that would have to have
131. Proposed Oversight, 55 Fed. Reg. 31,118, 31,121. These categories were:
1.Plants and animals resulting from natural reproduction or traditional
breeding techniques.
2.Microorganisms modified through chemical or physical mutagenesis, or
through natural processes of DNA mobility.
3.Plants regenerated from tissue culture.
4.Organisms with insertions of non-coding, non-expressed DNA sequences.
5.Organisms resulting from deletions, rearrangements and amplifications
within a single genome.
6.Organisms with new phenotypic traits conferring no greater risk to the tar-
get environment than a "safe" parental strain.
Id. Categories 5 and 6 especially went far beyond previous formulations; the BSCC,
for instance, had included only categories 1-4 on its draft list. See id. at 31,119. Cate-
gories 5 and 6 would exempt many organisms which could never have occurred natu-
rally or by traditional breeding methods.
132. Federal Oversight, 57 Fed. Reg. 6753, 6758.
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been done before an agency could have adopted them). Sec-
ond, the categories were based only on organisms, rather than
on introductions as a whole (including such factors as the
character of the target environment).133
It is a laudable development that the categories presented
in the Oversight Principles document (informed as they were
by the Competitiveness Council's desire to unburden biotech-
nology firms) were seen to be a case of too much too soon.
However, the Federal Oversight document is far from re-
jecting a category based approach: it asserts that "the concept
of categories for exclusion may nonetheless remain useful in
appropriate statutory circumstances. '"13 ' For example, the
Federal Oversight document suggests that under TSCA, the
EPA could exclude categories from oversight on the grounds
that the organisms composing them presented either no
"new" properties or no "unreasonable risk. 13 5
This article previously questioned the notions that genet-
ically modified organisms are not "new,"' 36 and also ques-
tioned both the sufficiency of biotechnology risk assessment
and the use of the Federal Oversight document's definition of
"unreasonable risk.' 1 37 This section addresses the use of this
methodology to generate categories of exclusion.
The reason for this analysis is that even if the proposi-
tions of product over process, risk-based regulation, and fa-
miliarity as the basis for risk assessment are accepted as the
133. These two objections can be generalized to yield the following: the catego-
ries were simply too broad to capture the reality of different types of risk, different
types of target environments, and different statutory mandates. The following text
argues that the Federal Oversight document has not remedied this defect.
134. Federal Oversight, 57 Fed. Reg. 6753, 6759.
135. Id. at 6759. TSCA applies to "new chemicals," TSCA §§ 4(9), 5(a)(1)(A), 15
U.S.C. §§ 2602(9), 2604(1)(a)(A) (1988). The Federal Oversight document thus sug-
gests that some genetically modified organisms might not be "new" in this sense be-
cause the modification involved resulted in no new phenotypic properties (perhaps
the simplest example would be a DNA "marker" insert with no effect on the organ-
ism's properties). TSCA provides for regulation of toxic substances which pose "un-
reasonable risk." 15 U.S.C. §§ 2604(f), 2605(a). It has already been suggested that
TSCA's definition of unreasonable risk is by no means the same as that elaborated in
the Federal Oversight document. See supra note 104, and accompanying text.
136. See supra text accompanying notes 114-28.
137. See supra notes 104-13 and accompanying text.
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basis for biotechnology regulation, using them to generate en-
tire classes of exempt organisms may not be justified. Because
the other principles are so little oriented to the "big picture"
of biotechnology's cumulative effects, this last step may be the
place to introduce a dose of broader vision. This stance is also
warranted because the ecological risks at issue are potentially
irreversible. As William Hines has written, "in dealing with
irreversible destruction of natural environments, the state of
the art in [cost-benefit analysis] suggests that it is wise to err
on the side of preservation." 188 Finally, we should be hesitant
to employ the exemption approach because regulatory exemp-
tions themselves tend to be irreversible. The D.C. Circuit, in
invalidating the EPA's exemption of certain classes of point
source water polluters from the permit requirements of the
Clean Water Act, addressed this problem, stating that "[a]n
exemption tends to become indefinite: the problem drops out
of sight, into a pool of inertia, unlikely to be recalled in the
absence of crisis or a strong political protagonist.'" 13 9
One argument against developing categories of exempt or-
ganisms is based on the observation that this approach will be
less responsive to scale effects and to the effects of widespread
patterns of use. 40 A major goal of the Federal Oversight docu-
ment is to avoid burdening the developing U.S. biotechnology
industry with regulatory red tape."' If this effort is successful,
138. N. William Hines, A Decade of Nondegradation Policy in Congress and the
Courts: The Erratic Pursuit of Clear Air and Clean Water, 62 IOWA L. REV. 643, 652
(1977).
139. Natural Resources Defense Council v. Costle, 568 F.2d 1369, 1382 (D.C. Cir.
1977). As an alternative to EPA's exemptions, the court suggested the practice of
"general permitting," in which classes of polluting sources in a given region are given
five-year permits. While reducing the administrative costs through grouping numer-
ous sources into a single class, this approach keeps the sources in the regulatory sys-
tem, thus avoiding the possibility that they would "drop out of sight." The general
permitting idea will be discussed at length in the concluding section of this article.
140. Cf. Tiedje, et al. supra note 6, at 304 (discussing risk effects of varying
scales and patterns of use). Note that the size of an introduction is not one of the
factors the Oversight Principles takes into account. Federal Oversight, 57 Fed. Reg.
6753, 6757.
141. See Press Release from Council on Competitiveness, Streamlining Federal
Regulation of Biotechnology Products (Feb. 24, 1992) (noting that one goal of the
Federal Oversight document is to remove unnecessary regulatory barriers to the de-
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uses will multiply radically as the biotechnology industry de-
velops and expands. This, in turn, raises the specter of the
cumulative effects of individually safe organisms. Past experi-
ence with pesticides has made some leery of biotechnology's
uncertainties:
Consideration only of the incremental effects of individ-
ual chemical pesticides is what has placed us in the cur-
rent fix, in which the cumulative effects of multiple low-
risk toxicants add up to substantial risks. Similarly, it is
not just the individual introductions of organisms that
deserve attention, but how society chooses to utilize this
kind of increased capability to manipulate the
environment. 1,2
Thus, deregulating individual classes of organisms addresses
only the "incremental" effects induced by such organisms.
The "cumulative" effects of such organisms are thus removed
from regulatory oversight, making it likely that problems aris-
ing from these cumulative effects would probably not be ad-
dressed until they reached dangerous proportions.
It would be wise to consider the release of genetically
modified organisms as a unified and radical human program
of recreating our environment to suit our needs. 11s Thus, regu-
lators should try to track the cumulative and long term effects
of the project. However, the regulatory approach based on
creating categories of exclusion from oversight directly frus-
trates such broad tracking. Exempt organisms no longer gen-
erate useful information because they are out of a regulator's
consideration.
Interestingly, the Administration has moved far beyond
the recommendations of many of its advisors in the exclusion-
velopment of biotechnology products).
142. Simon A. Levin, An Ecological Perspective, in THE GENETIC REVOLUTION 45,
52 (Bernard D. Davis ed., 1991).
143. Courts initially considered the view that the release of genetically modified
organisms had a unified, programmatic aspect (with the possibility of cumulative or
synergistic effects), see Foundation on Economic Trends v. Heckler, 756 F.2d 143,
159-60 (D.C. Cir. 1985), but ultimately adopted the incrementalism characteristic of
the Administration's approach.
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category approach. For instance, the cumulative effects prob-
lem was acknowledged by the National Academy of Sciences
in its "Key Issues" report. 144 But, in the years since 1987, it
has apparently dropped out of the Administration's view. Fur-
thermore, the Administration has also departed from the
"Framework for Decisions" report, inasmuch as that report's
recommendations - meant to apply only to small scale field
tests - have been extended to apply to all introductions
without being modified to account for problems of scale.145
Levin writes, "I am in agreement with the views of the ESA,
NAS, and Campbell in supporting small-scale and controlled
field tests as a necessary step in getting the products of bio-
technology into the field, but in urging caution where large-
scale commercial applications are contemplated. 146
Additionally, the category-based approach leaps beyond
the "Framework for Decisions" report in another crucial way.
Throughout, the report focused on "organisms" rather than
on "classes of organisms." It raised the possibility that, within
the context of small scale field tests, "[e]ventually, as our
knowledge increases, entire classes of introductions may be-
come familiar enough to require minimal oversight.1' 47 The
language used clearly indicates that this is a possibility for the
future, one unlikely to have materialized in the short span be-
tween the publication of the report and the publication of the
Federal Oversight document. Thus, the Federal Oversight
document seems to accept too readily the promise of exempt-
ing entire classes of organisms from federal oversight.1 48
In sum, the type of determinations required by the risk-
144. NATIONAL ACADEMY OF SCIENCES, KEY ISSUES, supra note 57, at 20-21.
145. Federal Oversight, 57 Fed. Reg. 6753, 6757 ("not limited to small-scale field
trials").
146. Simon Levin, supra note 142, at 57; see also Tiedje, et al., supra note 6, at
304 (also advocating small-scale field testing but expressing more hesitancy where
large-scale introductions are at issue).
147. NATIONAL RESEARCH COUNCIL, FRAMEWORK FOR DECISIONS, supra note 9, at
5.
148. Cf. Tiedje, et al., supra note 6, at 307-08 (supporting the category based
approach in principle, but finding that there is not currently enough scientific knowl-
edge to accurately define such categories; advocating in the meanwhile the use of
case-by-case review).
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based familiarity approach are, at the present state of our
knowledge, not suited to heavy use of the exclusion category
regulatory strategy. The inherent uncertainty in the determi-
nation of familiarity, for example, is multiplied when the de-
termination is made for entire categories of organisms. In the
case of biotechnology, "case-by-case review is currently the
most scientifically sound regulatory approach." 1 9 Therefore,
it would be prudent, at least for the time being, to avoid ex-
empting whole categories of introductions from regulatory
scrutiny. 1 0 Importantly, this does not mean that regulators
should not consider the effects of whole categories of orga-
nisms. A broader perspective would be wise, yet such a per-
spective would be impossible under an exclusion-based
approach.
149. Id. at 307, 310.
150. However, in May of 1992, the FDA announced that it would not promulgate
special rules for regulating genetically engineered foods. Statement of Policy: Foods
Derived From New Plant Varieties, 57 Fed. Reg. 22,984 (1992). The Council on Com-
petitiveness reportedly lobbied for the FDA to adopt this policy. Warren E. Leary,
Gene-Altered Food Held by the F.D.A. to Pose Little Risk, N.Y. TIMES, May 26, 1992,
at Al.
The policy is the first implementation of the Federal Oversight document; the
policy's contours follow the fundamental principles announced by the Federal Over-
sight document. See 57 Fed. Reg. 22,984, 22,989-91. For instance, in line with the
Federal Oversight document's stand on the product/process debate, the FDA has said
that genetically engineered foods are not inherently dangerous and, thus, such foods
do not require special regulatory attention. 57 Fed. Reg. 22,984, 22,984-85. Second,
the policy states that only genetically engineered foods which are not "substantially
similar" to naturally occurring foods will require pre-market testing and approval. 57
Fed. Reg. 22,984, 22,985.
This is essentially an application of the "familiarity" inquiry suggested by the
Federal Oversight document. But most importantly, the FDA policy is an example of
the Federal Oversight document's disregard for public risk perceptions. See supra
notes 92-103 and accompanying text. This can be seen most graphically in the fact
that the FDA policy does not require any special labelling for genetically engineered
foods. 57 Fed. Reg. 22,984, 22,991. Thus, consumers are deprived of any chance of
making their own decision about whether they wish to accept whatever risks might
accompany genetically engineered foods.
An early response to the policy was the Foundation on Economic Trends' boycott
of genetically engineered foods by more than 1000 chefs from premiere restaurants.
Chronicle: Genetically engineered foods? Not in their kitchens!, N.Y. TIMES, July 30,
1992, at B6.
38http://digitalcommons.pace.edu/pelr/vol10/iss1/8
BIOTECHNOLOGY OVERSIGHT
IV. Reforming the Scope of Federal Biotechnology
Oversight
Two factors have placed American biotechnology regula-
tion on the wrong track. First, agencies have been forced to
regulate biotechnology under statutes that were not enacted
with biotechnology in mind. Agencies have been able to make
relatively strong jurisdictional arguments for their authority
to regulate biotechnology under these statutes, but they have
paid a price. Regulatory programs with the most judicial legit-
imacy are not necessarily the most rational programs for ad-
ministering biotechnology.
Second, contemporary trends in risk assessment, compar-
ative risk analysis, and the application of cost-benefit analysis
to regulation have made our regulatory regime ill-equipped to
identify and regulate the risks of large-scale agricultural bio-
technology. Because such theoretical trends tend to mask the
need for political choices, even in purportedly "objective" reg-
ulatory programs, these trends have created a smoke screen
that has hidden - rather than solved - the problems created
by the lack of specific legislative guidance.
A. Is Legislative Guidance Required?
Would the best solution to these problems be to follow
the German example and ask Congress to provide more ex-
plicit legislative guidance? 1 1 The Administration is emphati-
cally against this idea, 152 not just because of its adversarial re-
lation to Congress, but also because it senses that popular
sentiment (however misguided by improper heuristics) may be
against a laissez-faire approach to biotechnology develop-
ment.153 Further inflaming popular sentiment by ignoring the
need for a comprehensive regulatory framework for biotech-
nology, however, is unlikely to be the best approach. In the
long run, waiting for a crisis might be worse for the developing
151. See supra note 130 and accompanying text.
152. COMPETITIVENESS COUNCIL, supra note 1, at 14.
153. See NEW DEVELOPMENTS IN BIOTECHNOLOGY, supra note 2, at 45-49.
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industry than taking some time now to formulate a more ra-
tional regime.
On the other hand, there is no reason to suspect that
Congress is better equipped than the Executive to develop a
rational regulatory policy for biotechnology. The necessary
technical competence and close familiarity with a specialized
subject area are much more in the province of administrative
agencies. Often, when Congress tries to put too short a leash
on administrative discretion, the results are inefficient. 54
John Applegate has tried to solve this dilemma by drawing a
more refined distinction between the respective spheres of
Congress and agencies. 155 Under Applegate's theory, it is Con-
gress' job to set broad regulatory priorities, which the agencies
then have wide discretion to apply in setting their own agen-
das. The problem with current biotechnology regulation, how-
ever, is not that the Administration is unsure of its priorities,
but that its regulatory approach itself is simply not suited to
biotechnology products.
The strongest reason for legislative intervention is that
the current regime of biotechnology regulation is on the wrong
trajectory. As biotechnology firms develop and as more firms
enter the field, the agencies will only be forced further along
this trajectory. This is the type of situation likely to end in a
crisis which can often be more damaging to an industry than
an extra regulatory burden at the outset would have been. In
order to avert this, it might be necessary for Congress to step
in. The proposals made below, however, are based on the be-
lief that the Administration and its agencies still have the
chance to craft, under existing statutes, a rational biotechnol-
ogy policy.
B. Proposal for Reformed Principles of Biotechnology
Oversight
The Federal Oversight document is an over-arching pol-
154. See generally Erik H. Corwin, Congressional Limits on Agency Discretion:
A Case Study of the Hazardous and Solid Waste Amendments of 1984, 29 HARv. J.
ON LEGis. 517 (1992).
155. Applegate, Worst Things First, supra note 80, at 332-34.
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icy statement which guides agency regulation of biotechnology
products. Remaining within that framework, the following
proposals attempt to describe a better approach to both risk
assessment and risk management. Specifically, the proposals
are an attempt to remedy flaws in the risk-based "familiarity"
methodology and the use of such methodology in generating
categories of organisms exempt from federal oversight.
1. Broadening Risk Assessment
There are two major problems with the current concept
of risk based regulation. First, it systematically underrates
"soft" risks, second-order risks, cumulative or global risks,
and public risk perceptions. This defect is exacerbated by the
Federal Oversight document's use of a cost-benefit definition
of "unreasonable risk." Second, in the area of biotechnology,
quantitative risk assessment is an uncertain science. As both
sides have recognized, this uncertainty involves numerous pol-
icy judgements.'56
At the very least, agencies should be instructed to make
more explicit the policy implications of "purely scientific" risk
assessment practices. Moreover, agencies should compensate
for the limitations of quantitative risk assessment and cost-
benefit analysis. They can do this in two ways. First, recogniz-
ing that the risks presented by genetically modified organisms
are indeed different than the risks presented by hazardous
chemicals, they should use risk assessment procedures which
are better adapted to the complex interaction of ecosystems
over time. Second, in situations where risk assessment leads to
uncertainty, precisely the factors left out by quantitative risk
assessment should be given more weight. Specifically, given
the potential for catastrophic or irreversible risks, the public
perception of "dread" risk, and Congress' general conserva-
tism on toxins in most statutes under which biotechnology is
regulated, 157 the policy bias when the risk level is uncertain
156. Compare Latin, supra note 82 (asserting that quantitative risk assessment
hides substantial bias toward under-regulation), with Gramm, supra note 90 (OMB
officer complaining that EPA risk assessment hides bias toward overregulation).
157. See Latin, supra note 82, at 135-36. This is evident in Congress' frequent
19921
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should favor considering, rather than ignoring, hard to quan-
tify risks.
The two failings of current risk assessment suggest that
the process should be broadened to take better account of the
types of risk common to biotechnology products. Also, to the
extent that the substantial uncertainty cannot be resolved in a
given case, the policy arguments favor a more pro-regulatory
stance than is currently being used.
2. Shifting the Costs of Uncertainty
As a corollary, these reforms would lead to a new position
on the product-process debate. The current position, that
there is "nothing new" about the products of genetic engineer-
ing, would have to be softened - although not to the extent
that genetic engineering would be considered risky per se.
Rather, biotechnology products would face a more stringent
burden in proving their safety. s15  This burden would be a di-
rect consequence of the reforms in risk assessment sketched
above. If these reforms were enacted, the biotechnology indus-
try would pay a higher price for uncertainty: to the extent
that assessments of biotechnology products' safety remained
uncertain, the policy considerations mentioned above would
weigh in favor of regulation rather than deregulation. 159
use of the "ample margin of safety" requirement in these statutes. Requiring agencies
to establish standards with an ample margin of safety is tantamount to requiring
that, where risk assessment for a given substance leads to uncertainty, an agency's
bias should be to regulate, rather than ignore, the substance.
158. Cf. Tiedje, et al., supra note 6, at 310-11 (recommending modified product
over process formula, under which products of genetic engineering will often receive
closer scrutiny than non-modified organisms); see also Shapiro, supra note 19, at 24-
25 (discussing problems with the EPA's regulation of biotechnology under TSCA,
where the EPA has the burden of proving an organism's danger, as opposed to indus-
try having the burden of proving an organism's safety).
159. Since its restrictive beginnings with the 1976 NIH Guidelines, the history of
biotechnology regulation has been a history of steadily moving the burden of dispel-
ling uncertainty onto potential regulators. Compare Guidelines for Research on Re-
combinant DNA Molecules, 41 Fed. Reg. 27,902, with Federal Oversight, 57 Fed. Reg.
6753. The Federal Oversight document is the current high-water mark in this direc-
tion. Federal Oversight, 57 Fed. Reg. 6753, 6757-58. The trend is also evident in the
courts. Compare Foundation on Economic Trends v. Heckler, 756 F.2d 143 (D.C. Cir.
1985) (uncertainty weighs against those wishing to release organisms) with Founda-
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Such a regime would have the further beneficial effect of
inducing firms to pool their resources in order to generate the
scientific data needed to demonstrate their products' safety.160
This would be beneficial because: (1) firms would internalize
some of the government's information costs in regulating their
products, (2) firms are usually in a better position to generate
reliable data on products with which they have extensive ex-
perience, and (3) firm pooling of information gathering re-
sources would tend to facilitate a "big picture" approach that
took account of biotechnology's effects across the board.
3. Modifying the Familiarity Approach
This modified product-process approach should also af-
fect the familiarity inquiry. An analogy to past, safe introduc-
tions constitutes a reasonable basis for regulation, but it relies
on at least two important policy questions that are currently
unanswered: (1) how similar does a proposed introduction
have to be to a past introduction and (2) how safe does the
past introduction itself have to be? To the extent that each of
these inquiries is ignored, the danger appears that risky bio-
technology products will gradually progress into widespread
use simply because no disaster has yet occurred.
Two steps can be taken to reform the familiarity ap-
proach. First, it should not be substituted completely for a
method of risk assessment based on calculating an introduc-
tion's absolute risk, independent of its similarity to other in-
troductions. Risk assessment should not proceed only by anal-
ogy. This principle is especially important in an industry like
biotechnology, where new organisms are developed at a rapid
pace, but their effects may not be felt for many years. The
tion Economic Trends v. Thomas, 637 F. Supp. 25 (D.D.C. 1986) (uncertainty weighs
against those opposing release) and Foundation on Economic Trends v. Thomas, 661
F. Supp. 713, 718 (D.D.C. 1986) (parties opposing release may no longer have stand-
ing because of uncertainty of alleged risk). See also Stewart, supra note 76, at 223-24.
160. See generally HARNESSING SCIENCE FOR ENVIRONMENTAL REGULATION (John
D. Graham, ed., 1991) (discussing the Chemical Industry Institute of Toxicology
(CIIT) and the Health Effects Institute (HEI), both industry-funded groups which
generate scientific data used in regulation, and claiming that such groups will play a
larger role in the coming years).
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combination of these two factors means that only a method of
risk assessment based on some absolute standard will be able
to provide a guarantee of safety.
Second, to the extent comparability determinations be-
tween two introductions contain uncertainty, an attempt
should be made to minimize the progressive accumulation of
uncertainties described above.161 This could be achieved by
establishing relatively stringent standards for acceptable
levels of uncertainty and by evaluating the level of uncer-
tainty for two introductions in light of the absolute level of
safety for the previous "safe" introduction.
4. Reforming Risk Management
The foregoing methodological recommendations would re-
quire that regulators be more responsive to (1) the types of
risk presented by biotechnology, (2) the uncertainty surround-
ing undertaken risks, and (3) public perceptions of these risks.
The remaining part of this proposal addresses the remaining
question: how should this new methodology be used in deter-
mining the scope of oversight?
On the one hand, given the uncertainties involved, the
possibility of irreversible environmental damage, public anxi-
ety, and the lack of support from some of the Administra-
tion's own scientific advisors, the strategy of exempting whole
categories of genetically modified organisms from oversight
seems rash. Indeed, the Federal Oversight document acknowl-
edged that this strategy is problematic, but the document did
not abandon the strategy. On the other hand, as The Presi-
dent's Council on Competitiveness notes, we stand to lose a
great deal from an overly restrictive regime."' In many cases,
stringent case-by-case review would impose unjustifiable costs
on a fledgling industry, an industry that is likely to contribute
greatly to international competitiveness. The Federal Over-
sight document seeks to avoid this possibility by replicating
the narrow framing procedures of quantitative risk assessment
161. See supra notes 119-26 and accompanying text.
162. See COMPETITIVENESS COUNCIL, supra note 1, at 11.
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at the level of risk management through the cost-benefit in-
terpretation of reasonable risk. This, however, results in a
gross overcompensation.
A compromise could be achieved with a system of general
permitting. In such a system, the risk assessment methodol-
ogy described above would be used to rank categories of orga-
nisms according to risk. Categories that did not appear to
pose substantially greater risk than categories of unmodified
organisms that previously had been released safely (i.e., the
comparability inquiry) would be made into general permit
categories.163 These categories would be exempt for the period
of the permit from further statutory requirements, but they
would not be overlooked as would be the case under the Fed-
eral Oversight document. The permits could serve a signifi-
cant "information-forcing" function. For instance, they could
be used as probationary periods during which firms would be
required to show the safety of releases in their particular cate-
gory. If at the end of a period, a firm could not make such a
showing, that category would be subject to more stringent
regulation.
The general permitting approach has the advantage of al-
lowing "safe" introductions to proceed without further regula-
tory processing, but at the same time it would allow the Ad-
ministration to maintain a continual monitoring ability over
these organisms. A further advantage is that such monitoring
would not be limited to individual organisms, but would also
consider the effects of classes of organisms. This broader focus
would help in the assessment of the cumulative effects of bio-
technology, a crucial function that the current regime is una-
ble to carry out.
163. Although it is impossible to predict the results of the revised risk assess-
ment recommended here, it is likely that the general permit categories would be nar-
rower than the exemption categories suggested by the Oversight Principles. Specifi-
cally, categories 5 (non-coding regulatory regions) and 6 (inter-generic combinations
similar to safe organisms) might not pass muster, or would pass only in narrower
form.
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5. Expanding the Role of the Biotechnology Science Co-
ordinating Council
This scheme would require a strong contribution from the
Biotechnology Science Coordinating Council (BSCC). Agen-
cies would gather data on general permit classes under rele-
vant statutes and would then pass the information on to the
BSCC for synthesis. If the BSCC found that a given category
of organisms had unanticipated adverse effects, either in indi-
vidual cases or cumulatively as a group, the BSCC could rec-
ommend non-renewal or revocation of that group's permit. If
a particular subgroup of organisms was the source of trouble,
the BSCC could call for a redefinition of the permit
category. 164
A reinvigorated BSCC166 will be more necessary as bio-
technology firms emerge and as their products begin to put
more pressure on a statutory framework not designed specifi-
cally with them in mind. By giving the BSCC a stronger role
as analyst of the cumulative, class-by-class, effects of biotech-
nology, it is more likely that the coordinated framework will
be able to cope successfully with the increased pressure.1 6
With a central oversight body, it is also less likely that we will
experience a disastrous accident due to biotechnology's
broader, cumulative effects. And finally, if the new BSCC
were to put itself in closer touch with the public,1 67 it would
provide an ideal way to increase the public legitimacy of bio-
technology regulation at the most global stage of the process.
164. The BSCC's recommendations would not be binding on agencies; rather,
they would provide an informational basis upon which the administration (most
likely OMB) could base an executive policy that would guide agency action. Under
this conception, the BSCC's function is not to impose policy, but to synthesize inter-
agency information into a basis for policy decisions.
165. See Sidney A. Shapiro, supra note 19, at 32-36.
166. See generally NEW DEVELOPMENTS IN BIOTECHNOLOGY, supra note 2, at 28-
29 (discussing possibility of interagency task force for generating data on the safety of
environmental releases of modified organisms).
167. See generally Sidney A. Shapiro, supra note 19, at 54-58 (discussing strate-
gies for increasing public participation in biotechnology regulation). While Professor
Shapiro's discussion is organized around the strategic goal of "greater public accept-
ance of new technologies," it is also possible to view public participation as an end in
itself.
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V. Conclusion
Current biotechnology policy, exemplified by the Federal
Oversight document, is on the wrong track. This is not to say
that its anticipated destination (increased domestic productiv-
ity and international competitiveness) is an unworthy goal.
But in the long run, this goal will only be reached through a
rational regulatory policy. As is all too well known, cata-
strophic accidents in the world of high technology, even if
highly unlikely, can lead to legitimation crises that danger-
ously impede or even halt an industry's development. A re-
formed Federal Oversight document, as sketched in this arti-
cle, constitutes a regulatory approach better suited to the
unique risks posed by biotechnology - one more likely to en-
joy public credibility and less likely to allow such crises to
occur.
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